Cytogenetics in the management of T-cell acute lymphoblastic leukemia (T-ALL): Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Cytogenetics
Diagnosis
Fluorescence in situ hybridization (FISH)
Karyotype
Prognosis
T-cell acute lymphoblastic leukemia
Journal
Current research in translational medicine
ISSN: 2452-3186
Titre abrégé: Curr Res Transl Med
Pays: France
ID NLM: 101681234
Informations de publication
Date de publication:
19 Nov 2023
19 Nov 2023
Historique:
received:
03
07
2023
revised:
13
11
2023
accepted:
17
11
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
28
11
2023
Statut:
aheadofprint
Résumé
Molecular analysis is the hallmark of T-cell acute lymphoblastic leukemia (T-ALL) categorization. Several T-ALL sub-groups are well recognized based on the aberrant expression of specific transcription factors. This recently resulted in the implementation of eight provisional T-ALL entities into the novel 2022 International Consensus Classification, albeit not into the updated World Health Organization classification system. Despite this extensive molecular characterization, cytogenetic analysis remains the backbone of T-ALL diagnosis in many countries as chromosome banding analysis and fluorescence in situ hybridization are relatively inexpensive techniques to obtain results of diagnostic, prognostic and therapeutic interest. Here, we provide an overview of recurrent chromosomal abnormalities detectable in T-ALL patients and propose guidelines regarding their detection. By referring in parallel to the more general molecular classification approach, we hope to offer a diagnostic framework useful in a broad clinical genetic setting.
Identifiants
pubmed: 38016418
pii: S2452-3186(23)00055-7
doi: 10.1016/j.retram.2023.103431
pii:
doi:
Types de publication
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
103431Informations de copyright
Copyright © 2023. Published by Elsevier Masson SAS.